Global Pneumococcal Vaccination Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Pneumococcal Vaccination Market Insights, Forecast to 2034
Pneumococcal Vaccine is a kind of vaccine used to prevent infection caused by pneumococcal bacteria.
Global Pneumococcal Vaccination market is expected to reach to US$ 8782 million in 2024, with a positive growth of %, compared with US$ 7841.5 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Pneumococcal Vaccination industry is evaluated to reach US$ 16100 million in 2029. The CAGR will be 10.6% during 2024 to 2029.
The pneumococcal vaccination market is driven by the increasing awareness of the importance of vaccination and the rising incidence of pneumococcal infections. Pneumococcal vaccines are crucial in preventing diseases caused by Streptococcus pneumoniae bacteria, such as pneumonia, meningitis, and bacteremia. The rise in the geriatric population and the need for immunization against respiratory infections contribute to market growth as pneumococcal vaccines offer significant benefits in reducing morbidity and mortality. Moreover, advancements in vaccine technology, such as the introduction of conjugate vaccines for broader protection, have improved vaccine efficacy. However, the market also faces challenges, including vaccine supply constraints and the need for continuous research to address emerging pneumococcal serotypes and strains. Additionally, addressing vaccine hesitancy and increasing vaccination coverage in underserved populations can pose obstacles for comprehensive disease prevention. To succeed, companies must focus on research and development to offer innovative and affordable pneumococcal vaccines, collaborate with healthcare providers to promote vaccination recommendations, and address the challenges to meet the increasing demand for effective and accessible protection against pneumococcal infections.
Report Covers
This report presents an overview of global Pneumococcal Vaccination market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Pneumococcal Vaccination market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
Pfizer
GSK
MSD
CDIBP
WALVAX
Sinovac
Bio Kangtai
Segment by Type
PPSV 23
PCV 13
PCV 10
Child
Adult
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Pneumococcal Vaccination plant distribution, commercial date of Pneumococcal Vaccination, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Pneumococcal Vaccination introduction, etc. Pneumococcal Vaccination Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Pneumococcal Vaccination
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Global Pneumococcal Vaccination market is expected to reach to US$ 8782 million in 2024, with a positive growth of %, compared with US$ 7841.5 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Pneumococcal Vaccination industry is evaluated to reach US$ 16100 million in 2029. The CAGR will be 10.6% during 2024 to 2029.
The pneumococcal vaccination market is driven by the increasing awareness of the importance of vaccination and the rising incidence of pneumococcal infections. Pneumococcal vaccines are crucial in preventing diseases caused by Streptococcus pneumoniae bacteria, such as pneumonia, meningitis, and bacteremia. The rise in the geriatric population and the need for immunization against respiratory infections contribute to market growth as pneumococcal vaccines offer significant benefits in reducing morbidity and mortality. Moreover, advancements in vaccine technology, such as the introduction of conjugate vaccines for broader protection, have improved vaccine efficacy. However, the market also faces challenges, including vaccine supply constraints and the need for continuous research to address emerging pneumococcal serotypes and strains. Additionally, addressing vaccine hesitancy and increasing vaccination coverage in underserved populations can pose obstacles for comprehensive disease prevention. To succeed, companies must focus on research and development to offer innovative and affordable pneumococcal vaccines, collaborate with healthcare providers to promote vaccination recommendations, and address the challenges to meet the increasing demand for effective and accessible protection against pneumococcal infections.
Report Covers
This report presents an overview of global Pneumococcal Vaccination market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Pneumococcal Vaccination market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Pfizer
GSK
MSD
CDIBP
WALVAX
Sinovac
Bio Kangtai
Segment by Type
PPSV 23
PCV 13
PCV 10
Segment by Application
Child
Adult
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Pneumococcal Vaccination plant distribution, commercial date of Pneumococcal Vaccination, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Pneumococcal Vaccination introduction, etc. Pneumococcal Vaccination Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Pneumococcal Vaccination
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices